- ... for pediatric Burkitt lymphoma remains to be elucidated. Activating mutations in the transcription factor TCF3 and inactivating mutations in its negative regulator ID3 are observed in approximately 70% of ...
- ... the BOLERO-2 trial. Alpelisib plus endocrine therapy Activating mutations in PIK3CA are identified in approximately 40% of hormone receptor–positive and HER2-negative breast cancers. Alpelisib is an alpha-specific PI3K ...
- ... mutations in MAP2K1 (which codes for MEK) were activating, as indicated by their induction of ERK ... cases.[ 26 ] Studies support the universal activation of ...
- ... IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK ... and genetic characteristics of RAG mutations in 15 Chinese patients with SCID and Omenn ...
- ... Vogelstein B, Meyerson M, Sellers WR, Neel BG. Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene ... Cavé H, Gelb BD, Neel BG, Tartaglia M. Activating mutations affecting the Dbl homology domain of SOS2 cause ...
- ... the following: Evidence of WNT pathway activation by activating mutations in the CTNNB1 gene is common.[ 69 - 71 ] ... 30%) than in nonanaplastic cases (11.2%).[ 117 ] Activating mutations at codon 44 (p.P44L) were identified in ...
- ... Greulich H, Morris SW, Meyerson M, Look AT. Activating mutations in ALK provide a therapeutic target in neuroblastoma. ... S, Amiel J, Delattre O. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. ...
- ... phenotypes in children with hyperinsulinism caused by glucokinase activating mutations. Diabetes. 2009; 58 :1419–27. [ PMC free article : ...
- ... unless there is hemorrhage into the tumor. Somatic activating mutations of GNAQ and GNA11 have been found to ... UM, Couto JA, Hann S, et al.: Somatic Activating Mutations in GNAQ and GNA11 Are Associated with Congenital ...
- ... JB, Olsen BR. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell. 1996; ...
146 results